Liposome comprising rapamycin or a derivative thereof and use thereof in therapy
The present disclosure relates to a lipid-based formulation comprising rapamycin and derivatives thereof, and also relates to using the formulation for treatment of diseases or conditions, such as cancers, immuo-related disease, etc.
1. A liposome comprising a lipid ingredient encapsulating rapamycin or an analog thereof, or a prodrug or salt of rapamycin or its analog,
wherein: the lipid ingredient is:
(1) a combination of dipalmitoylphosphatidylcholine (DPPC), 1,2-Didecanoyl-sn-glycero-3-phosphocholine (DDPC), and PEGlated 1,2-Distearoyl-sn-glycero-3-phosphorylethanolamine (DSPE-PEG),
wherein (a) the DPPC, DDPC, and DSPE-PEG are respectively present in an amount of about 35% (w/w), about 27% (w/w), and about 23% (w/w), based on the dry weight of the total amount of the liposome, or (b) the DPPC, DDPC, and DSPE-PEG are present in a weight ratio of about 2.4:1.9:1.6; or
(2) a combination of DOPE (dioleoyl phosphatidyl ethanolamine), DDPC, and DSPE-PEG,
wherein (a) the DOPE, DDPC, and DSPE-PEG are respectively present in an amount of about 35% (w/w), about 27% (w/w), and about 23% (w/w), based on the dry weight of the total amount of the liposome, or (b) the DOPE, DDPC, and DSPE-PEG are present in a weight ratio of about 2.4:1.8:1.6;
the rapamycin analog is able to inhibit a mammalian target of rapamycin (mTOR); and
the amount of rapamycin or an analog thereof, or a prodrug or salt of rapamycin or its analog, based on the dry weight of the total amount of liposome, ranges from about 10% (w/w) to 25% (w/w).
2. The liposome of claim 1 , wherein the liposome is a poly(ethylene glycol) (PEG)-modified liposome.
3. The liposome of claim 1 , wherein the analog of rapamycin is selected from the group consisting of everolimus, temserolimus, tacrolimus, prerapamycin, zotarolimus, ridaforolimus, 7-epi-rapamycin, 7-thiomethyl-rapamycin, 7-epi-trimethoxyphenyl-rapamycin, 7-epi-thiomethyl-rapamycin, 7-demethoxy-rapamycin, 32-demethoxy-rapamycin, 2-desmethyl-rapamycin, and 42-O-(2-hydroxy)ethyl rapamycin, rapamycin oximes, rapamycin aminoesters, rapamycin dialdehydes, rapamycin 29-enols, O-alkylated rapamycin derivatives, water soluble rapamycin esters, alkylated rapamycin derivatives, rapamycin amidino carbamates, biotin esters of rapamycin, carbamates of rapamycin, rapamycin hydroxyesters, rapamycin 42-sulfonates, 42-(N-carbalkoxy) sulfamates, rapamycin oxepane isomers, imidazolidyl rapamycin derivatives, rapamycin alkoxyesters, rapamycin pyrazoles, acyl derivatives of rapamycin, rapamycin amide esters, rapamycin fluorinated esters, rapamycin acetals, oxorapamycins, and rapamycin silyl ethers.
4. The liposome of claim 1 , wherein the average particle size of the liposome ranges from about 100 nm to about 500 nm.
5. A liposome formulation comprising the liposome of claim 1 and a cryoprotectant.
6. The liposome formulation of claim 5 , wherein the cryoprotectant is a disaccharide.
7. The liposome formulation of claim 5 , wherein the cryoprotectant is sucrose or trehalose.
8. The liposome formulation of claim 5 , wherein the cryoprotectant based on the dry weight of the total amount of liposome ranges from about 80% to about 97% (w/w).
9. A method for treating a cancer, diabetes, obesity, neurological disease or genetic disorder and/or preventing an organ transplant rejection, in a subject, comprising administering a therapeutically effective amount of the liposome of claim 1 to the subject.